When does the Descovy patent expire?
The exact expiration date depends on which “Descovy” patent is being discussed, because Descovy (emtricitabine/tenofovir alafenamide) is protected by multiple patents covering different aspects (for example, drug composition, formulations, and methods of use). Patent expiry dates therefore vary across the specific patent numbers and jurisdictions involved.
How can you find the right Descovy patent and its expiry date?
To pin down a specific expiry date, you typically need:
- The patent number (or an identifier from a patent listing or settlement).
- The country or patent office (for example, the US vs. Europe).
- Whether you mean the end of the patent term, or a longer period created by regulatory exclusivity (which can extend market protection even if a patent expires).
If you share the country (US, EU, UK, etc.) and any patent number you’re looking at, the expiry can be determined for that specific right.
Does Descovy have exclusivity beyond patent expiry?
Even after a patent expires, market protection can continue through regulatory exclusivities tied to approval/marketing in a given region. So “patent expiry” and “when generics can launch” are not always the same date. The practical launch date is usually driven by the later of:
- patent expiration for relevant patents, and
- any applicable regulatory exclusivity or blocking periods.
What could change the answer: patent challenges and settlements
Patent expiry timelines often move in practice due to:
- patent litigation (including challenges brought by generic or biosimilar applicants),
- stays/settlements that delay launches even before the legal end date, and
- additional later-listed patents that may be asserted to block generic entry.
So two sources that cite different dates can both be “right,” depending on which patents and which legal events they cover.
If you’re trying to know when a generic can enter, what should you look for?
Search for the “launch eligibility” trigger in the relevant jurisdiction: the date when the last blocking patent and any exclusivities expire, plus any court-ordered stays/settlements. In the US context, this is often discussed through Hatch-Waxman listings and litigation outcomes; in other regions, the structure differs but the concept is similar: the last legally blocking protection wins.
Tell me the jurisdiction and patent you mean
Reply with either:
1) the country (e.g., US), and
2) the patent number (or a link/source you’re using),
and I can translate that into the specific expiry date and how it affects generic entry.
Sources: none provided in the prompt.